
via ACS
Going to the doctor might make you want to cry, and according to a new study, doctors could someday put those tears to good use.
In ACS Nano, researchers report a nanomembrane system that harvests and purifies tiny blobs called exosomes from tears, allowing researchers to quickly analyze them for disease biomarkers. Dubbed iTEARS, the platform could enable more efficient and less invasive molecular diagnoses for many diseases and conditions, without relying solely on symptoms.
Diagnosing diseases often hinges on assessing a patient’s symptoms, which can be unobservable at early stages, or unreliably reported. Identifying molecular clues in samples from patients, such as specific proteins or genes from vesicular structures called exosomes, could improve the accuracy of diagnoses. However, current methods for isolating exosomes from these samples require long, complicated processing steps or large sample volumes. Tears are well-suited for sample collection because the fluid can be collected quickly and non-invasively, though only tiny amounts can be harvested at a time. So, Luke Lee, Fei Liu and colleagues wondered if a nanomembrane system, which they originally developed for isolating exosomes from urine and plasma, could allow them to quickly obtain these vesicles from tears and then analyze them for disease biomarkers.
The team modified their original system to handle the low volume of tears. The new system, called “Incorporated Tear Exosomes Analysis via Rapid-isolation System” (iTEARS), separated out exosomes in just 5 minutes by filtering tear solutions over nanoporous membranes with an oscillating pressure flow to reduce clogging. Proteins from the exosomes could be tagged with fluorescent probes while they were still on the device and then transferred to other instruments for further analysis. Nucleic acids were also extracted from the exosomes and analyzed. The researchers successfully distinguished between healthy controls and patients with various types of dry eye disease based on a proteomic assessment of extracted proteins. Similarly, iTEARS enabled researchers to observe differences in microRNAs between patients with diabetic retinopathy and those that didn’t have the eye condition, suggesting that the system could help track disease progression. The team says that this work could lead to a more sensitive, faster and less invasive molecular diagnosis of various diseases — using only tears.
Original Article: ‘iTEARS’ could help diagnose diseases by isolating biomarkers in tears
More from: Wenzhou Medical University | American Chemical Society
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Biomarkers in tears
- Using Biomarkers to Determine Etiology, Predict Disease Course, and Target Therapy in Pediatric Pneumonia
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Today we'll ...
- Future of Cancer Biomarkers Market by 2030 | Trends and Predictions
The global Cancer Biomarkers market size was valued at USD 13682.86 million in 2022 and is expected to expand at a CAGR of 15.82 Percent during the forecast period, reaching USD 33033.58 million ...
- Biomarker testing is a critical part of cancer care
We use this information — called biomarkers — to inform us about prognosis, which medicines to use (or not use), when to change treatments, and for other reasons. Precision medicines that ...
- Cancer Biomarkers Market 2023 Offered In New Research Forecast Through 2032
This high-end research on Global Cancer Biomarkers Market 2023 by Key Players, Type and Application, Forecast to 2032 throws light on critical aspects of the market like size estimations ...
- Two Biomarkers May Diagnose Long COVID Brain Fog
Diagnosing the problem can also be challenging, because there have not been any reliable biomarkers for long COVID and diagnosis relies on how clinicians interpret the symptoms that patients report.
Go deeper with Google Headlines on:
Biomarkers in tears
[google_news title=”” keyword=”biomarkers in tears” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Molecular diagnosis
- Know How Molecular You's AI is Personalizing Healthcare
Discover how Molecular You is reshaping the future of healthcare through cutting-edge AI technology with Dr. Rob Fraser ...
- Point-of-Care Molecular Diagnostics Market Poised for Significant Growth, CAGR of 9.7% Expected from 2023 to 2033
The point-of-care molecular diagnostics market is poised for significant growth, with a projected valuation of US$ 4.4 billion in 2023 and an anticipated increase to US$ 11.1 billion by 2033, ...
- New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the ty ...
- Groundbreaking Report Reveals the Future of Diagnostics: Companion Diagnostics Set to Revolutionize Personalized Medicine - ResearchAndMarkets.com
The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's ...
- Molecular Diagnostics: Precision Medicine Propels Market to Reach $27.4 Billion by 2028
Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global molecular diagnostics market has witnessed ...
Go deeper with Google Headlines on:
Molecular diagnosis
[google_news title=”” keyword=”molecular diagnosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]